Eterna Therapeutics Inc. – NASDAQ:BTX
Eterna Therapeutics stock price today
Eterna Therapeutics stock price monthly change
Eterna Therapeutics stock price quarterly change
Eterna Therapeutics stock price yearly change
Eterna Therapeutics key metrics
Market Cap | 1.05M |
Enterprise value | N/A |
P/E | -0.07 |
EV/Sales | N/A |
EV/EBITDA | 0.35 |
Price/Sales | N/A |
Price/Book | 0.06 |
PEG ratio | N/A |
EPS | -4.25 |
Revenue | N/A |
EBITDA | -19.38M |
Income | -22.89M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEterna Therapeutics stock price history
Eterna Therapeutics stock forecast
Eterna Therapeutics financial statements
| Jun 2023 | 0 | -4.50M | |
|---|---|---|---|
| Sep 2023 | 51K | -5.59M | -10962.75% |
| Dec 2023 | 17K | -6.15M | -36194.12% |
| Mar 2024 | 47K | -6.64M | -14142.55% |
| 2022-04-15 | -0.12 | -0.16 |
|---|---|---|
| 2022-08-11 | -0.13 | -0.06 |
| Payout ratio | 0% |
|---|
| 2019 | 0.25% |
|---|---|
| 2020 | |
| 2021 | 0% |
| 2022 | 0.16% |
| 2023 | 0.17% |
| Jun 2023 | 46954000 | 43.08M | 91.77% |
|---|---|---|---|
| Sep 2023 | 52248000 | 48.68M | 93.18% |
| Dec 2023 | 49132000 | 46.89M | 95.46% |
| Mar 2024 | 49657000 | 53.06M | 106.87% |
| Jun 2023 | -3.87M | 0 | 312K |
|---|---|---|---|
| Sep 2023 | -5.82M | 0 | 8.54M |
| Dec 2023 | -4.66M | -19K | 7.70M |
| Mar 2024 | -3.74M | -97K | 1.38M |
Eterna Therapeutics alternative data
| Aug 2023 | 10 |
|---|---|
| Sep 2023 | 10 |
| Oct 2023 | 10 |
| Nov 2023 | 10 |
| Dec 2023 | 10 |
| Jan 2024 | 10 |
| Feb 2024 | 10 |
| Mar 2024 | 10 |
| Apr 2024 | 10 |
| May 2024 | 10 |
| Jun 2024 | 10 |
| Jul 2024 | 10 |
Eterna Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Jul 2023 | 954543 | 0 |
| Dec 2023 | 1562988 | 0 |
-
What's the price of Eterna Therapeutics stock today?
One share of Eterna Therapeutics stock can currently be purchased for approximately $7.2.
-
When is Eterna Therapeutics's next earnings date?
Unfortunately, Eterna Therapeutics's (BTX) next earnings date is currently unknown.
-
Does Eterna Therapeutics pay dividends?
No, Eterna Therapeutics does not pay dividends.
-
How much money does Eterna Therapeutics make?
Eterna Therapeutics has a market capitalization of 1.05M. Eterna Therapeutics made a loss 21.67M US dollars in net income (profit) last year or -$0.06 on an earnings per share basis.
-
What is Eterna Therapeutics's stock symbol?
Eterna Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "BTX".
-
What is Eterna Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Eterna Therapeutics?
Shares of Eterna Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Eterna Therapeutics have?
As Jul 2024, Eterna Therapeutics employs 10 workers.
-
When Eterna Therapeutics went public?
Eterna Therapeutics Inc. is publicly traded company for more then 34 years since IPO on 29 Aug 1991.
-
What is Eterna Therapeutics's official website?
The official website for Eterna Therapeutics is brooklynitx.com.
-
Where are Eterna Therapeutics's headquarters?
Eterna Therapeutics is headquartered at 1800 Aston Ave Ste 100, Carlsbad, CALIFORNIA.
-
How can i contact Eterna Therapeutics?
Eterna Therapeutics's mailing address is 1800 Aston Ave Ste 100, Carlsbad, CALIFORNIA and company can be reached via phone at +1 760 438 7400.
Eterna Therapeutics company profile:
Eterna Therapeutics Inc.
brooklynitx.comNASDAQ
10
Biotechnology
Healthcare
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Carlsbad, CALIFORNIA 92121
CIK: 0000748592
ISIN: US1140821000
CUSIP: 114082100
